Currently submitted to: JMIR Cancer
Date Submitted: Oct 19, 2025
Open Peer Review Period: Oct 20, 2025 - Dec 15, 2025
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
How Do Artificial Intelligence Applications in Breast Cancer Impact Health Equity, Particularly in Diagnosis, Treatment, and Outcomes of Diverse Groups: A Critical Literature Review
ABSTRACT
Background:
The integration of Artificial Intelligence (AI) in breast cancer care has the potential to impact health equity, yet the extent of this impact remains underexplored. Understanding how AI applications influence health disparities, including racial, ethnic, and socio-economic factors, is crucial for developing effective and equitable interventions.
Objective:
This review aims to provide a comprehensive analysis of current evidence on the impact of AI technologies on health equity in breast cancer (BC) care. It focuses on how AI influences disparities in diagnosis, treatment, and outcomes among different racial, ethnic, and socio-economic groups, and critically assesses the quality and robustness of studies evaluating AI interventions intended to address these inequities.
Methods:
Adhering to PRISMA 2020 guidelines for Systematic Reviews, this Critical Literature Review analyzed studies published between January 2019 and August 2024. A comprehensive literature search across Medline, Embase, Web of Science, and Scopus was conducted to identify peer-reviewed research addressing AI applications in breast cancer and their impact on health equity. Studies were evaluated for their focus on health equity outcomes, and methodological rigor. The quality of each study was assessed using the Public Health Critical Appraisal Checklist (PHCA) and the Ruling Out Bias Using Standard Tools in Machine Learning (ROBUST-ML) checklist.
Results:
The review included seven studies. The findings of the study highlighted three main themes of AI's role in reducing healthcare inequalities: forecasting biological and socio-economic factors affecting outcomes, enhancing decision-making fairness, and use of AI to reduce healthcare inequalities in a global context.
Conclusions:
The studies highlight AI’s potential in addressing health inequalities in breast cancer through its capacity to analyze complex datasets, incorporate race/ethnicity-specific models, and function in resource-limited settings. However, its impact depends heavily on data quality, dataset representativeness, and the ability to mitigate inherent model biases. Therefore, policymakers should focus on improving dataset inclusivity, establishing benchmark datasets, standardizing data collection, and addressing data poverty in low- and middle-income countries. Future researchers should ensure dataset representativeness and generalizability, conduct prospective or randomized controlled trials to assess real-world applications, and carefully select predictor variables through multidisciplinary collaboration. Adherence to standard reporting guidelines is also essential to enhance reproducibility and ensure the reliability of AI applications in breast cancer.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.